The Central Drugs Standard Control Organization’s Subject Expert Committee has granted Zydus Cadila’s three-dose vaccine emergency use authorization in India. The vaccine can be administered to people aged 12 and above.
‘Phase 3 clinical trials has been the largest trial so far in India for Covid-19 vaccines and the results show that primary efficacy of 66.6% for symptomatic RT-PCR positive cases.’
ZyCoV-D is a first of its kind DNA vaccine that produces the spike protein of the SARS-CoV-2 to elicit an immune response. It is an intradermal vaccine that has to be applied using a ‘needle-free injector’, which, the manufacturer says, will help in reducing side effects.
Earlier, Union Health Minister Mansukh Mandaviya, in a tweet, said: “Double good news for the nation! CDSCO_INDIA_INF approves the 1st DNA-based, needle-free COVID19 vaccine in the world ‘ZyCov-D’. Making children of India COVID-safe, this vaccine can be used for individuals aged 12 and above.
“‘ZyCov-D’ is the 6th approved COVID19 vaccine in India, and the 2nd indigenously developed one”, he said in another tweet.
The interim results from Phase 3 clinical trials, involving over 28,000 volunteers, showed primary efficacy of 66.6 percent for symptomatic RT-PCR positive cases. This has been the largest trial so far in India for Covid-19 vaccines.
Source: IANS
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsBit.us is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
